Agios reports additional Phase I data for ivosidenib in AML

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported data from 125 patients with isocitrate dehydrogenase 1 (IDH1) mutation-positive acute myelogenous leukemia (AML) in a Phase I trial showing

Read the full 252 word article

User Sign In